Agape ATP Corporation Common Stock earnings per share and revenue
On --, ATPC reported earnings of -- USD per share (EPS) for -- --, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q4 25, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cytosorbents Corp.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.09
Surprise
-76.47%
Nephros Inc.
Report Date
Mar 12, 2026 For Q4 25
Estimate
$0.01
Actual
$0.08
Surprise
+684.31%
Capricor Therapeutics Inc
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.55
Actual
-$0.62
Surprise
-12.56%
Kestra Medical Technologies, Ltd. Common Stock
Report Date
Mar 17, 2026 For Q3 26
Estimate
-$0.60
Actual
-$0.61
Surprise
-0.39%
Sundial Growers Inc. Common Shares
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.01
Actual
$0.04
Surprise
+499.62%
High Tide Inc. Common Shares
Report Date
Mar 17, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+447.68%
Sanara MedTech Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.11
Actual
$0.04
Surprise
-64.35%
FAQ
What were Agape ATP Corporation Common Stock's earnings and revenue for the latest quarter Q-- --?
For Q-- --, Agape ATP Corporation Common Stock reported EPS of --, Inline estimates by --, and revenue of --, -- -- expectations.
How did the market react to Agape ATP Corporation Common Stock's Q-- -- earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Agape ATP Corporation Common Stock expected to report next?
The next earning report is scheduled for Mar 30, 2026.
What are the forecasts for Agape ATP Corporation Common Stock's next earnings report?
Based on --
analysts, Agape ATP Corporation Common Stock is expected to report EPS of -- and revenue of -- for Q4 2025.